MSB Trading 2020 - a new dawn, page-534

Personally, I'm not going to condemn those suggesting $10 in the short-term are motivated by unwarranted ramping. On a cursory analysis, it would be natural to question why a return to the historical high is out of the question in the short term when the high was reached at a time without any approval (or, at least, without being within arm's reach of approval).

When you talk about being undervalued, are you speaking relative to the potential revenue that stands to be generated from an approval for SR-aGVHD in children? If so, I think you're about right. But from the conference call this morning, it seems like the analysts are already turning their minds to factoring in an extension to adult SR-aGVHD in the relatively near term. Beyond that, the market is going to factor in potential upside from C-19-related ARDS label extension, as well as CLBP and CHF treatments. It will be very interesting to see how the US markets react tonight.The US market probably has a better grip on those aspects and where the re-rate should land post-ODAC.